| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22054 |
| Drug |
Ibrutinib |
| Brand |
Imbruvica® |
| Indication |
In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. |
| Rapid review commissioned |
27/07/2022 |
| Rapid review completed |
02/09/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ibrutinib in combination with venetoclax compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/09/2022 |
| Pre-submission consultation with Applicant |
14/11/2022 |
| Full submission received from Applicant |
14/02/2023 |
